• The following formulations are approved:
  
  • 0.75mg in 0.75ml injections;
  • 3mg vaginal tablets;
  • 10mg pessaries.
  
  

• Injection: 500 micrograms in 1ml

• Injection: ergometrine maleate 500micrograms and oxytocin 5 units

• Tablets: 200 micrograms

• The following formulations are approved for use:
  
  • 10 units in 1ml injection
  • 5 units in 50ml syringes unlicensed.

• 10mg/2ml ampoule

• Approved formulations include:
  
  • 6.75mg in 0.9ml injection
  • 37.5mg in 5ml (7.5mg/ml) concentrate for IV infusion.
  
  

• Ampoules: 500micrograms/ml

• Dispersible tablets: 75mg

• Injection: 4mg/ml

• Spray: 400micrograms/dose

• Ampoules: 20% in 10ml

• Capsules: 5mg, 10mg

• For restricted use for the relief of symptoms of atrophic vaginitis, in women who have had treatment for gynaecological malignancyand where topical estriol is not a treatment option

• Nystatin 100,000 Pessaries (unlicensed)

• As per BASHH guidelines for non-albicans vulvovaginal candida or in azole resistance.

• Logynon®
• Logynon® ED
• Tri-Regol®

First Choice

• Rigevidon® (ethinylestradiol 30 microgram/levonorgestrel 150microgram)

Alternatives

• Cilique® (ethinylestradiol 35 microgram/norgestimate 250microgram)
• Femodene® (ethinylestradiol 30 microgram/gestodene 75 microgram)
• Femodene® ED (ethinylestradiol 30 microgram/gestodene 75 microgram)
• Gedarel 30/150® (ethinylestradiol 30 microgram/desogestrel 150 microgram)
• Levest® (ethinylestradiol 35 microgram/norgestimate 250microgram)
• Lizinna® (ethinylestradiol 35 microgram/norgestimate 250 microgram)
• Loestrin 30® (ethinylestradiol 30 microgram/ norethisterone 1.5mg)
• Lucette® (ethinylestradiol 30 microgram/drospirenone 3mg)
• Marvelon® (ethinylestradiol 30 microgram/desogestrel 150 microgram)
• Microgynon® 30 (ethinylestradiol 30 microgram/levonorgestrel 150 microgram)
• Microgynon® ED (ethinylestradiol 30 microgram/levonorgestrel 150 microgram)
• Millinette 30/75® (ethinylestradiol 30 microgram/ gestodene 75 microgram)
• Ovranette® (ethinylestradiol 30 microgram/levonorgestrel 150microgram)
• Ovysmen® (ethinylestradiol 35 microgram/norethisterone 500 microgram

• Evra® are self-adhesive patches releasing approximately 20 micrograms ethinylestradiol and 150 micrograms norelgestromin/24 hours.
  
  
  
  • Approved for use by a small number of women with gastrointestinal absorption problems or with compliance issues.
  
  
  
  

• Each wallet (28 film-coated tablets) contains in the following order:
  2 dark yellow tablets each containing 3 mg estradiol valerate
  5 medium red tablets each containing 2 mg estradiol valerate and 2 mg dienogest
  17 light yellow tablets each containing 2 mg estradiol valerate and 3 mg dienogest
  2 dark red tablets each containing 1 mg estradiol valerate

• Approved for
  • women who need HRT as well as contraceptive pill, and
  • for heavy menstrual bleeding (HMB)

• 20mcg ethinylestradiol and 3mg drospirenone

• Ethinylestradiol 2.7 mg, Etonogestrel 11.7 mg vaginal ring

• Co-cyprindiol should be reserved for those women requiring treatment for the androgenic conditions such as severe acne or moderately severe hirsutism. It is recommended that treatment be withdrawn 3 to 4 cycles after the androgenic condition(s) has/have completely resolved and that it is not continued solely to provide oral contraception. Venous thromboembolism occurs more frequently in women taking co-cyprindiol than those taking a low-dose combined oral contraceptive. Repeat courses may be given if the androgen-dependent condition(s) recur.
• Note: generic co-cyprindiol is much cheaper than Dianette®

First choice

• Cerelle® (desogestrel 75 microgram tablets).
• Cerazette® (desogestrel 75 microgram tablets).
• Zelleta® (desogestrel 75 microgram tablets).

Alternatives

• Norgeston® (levonorgestrel 30 microgram tablets).

• Replaces Implanon® and differs in that it is impregnated with radio opaque material.

• Approved formulations include:
  
  • Depo-Provera® - 150mg in 1ml depot injection;
  • Sayana Press® - 104mg/0.65ml S/C injection.
  
  

• Levonorgestrel 52mg in a T-shaped intra-uterine system. 
• For idiopathic menorrhagia. Especially in women requiring (reversible) contraception. Also used for protection from endometrial hyperplasia during oestrogen replacement therapy. Lasts for up to 5 years - for use in accordance with agreed guidelines.

• Levonorgestrel 13.5mg in a T-shaped intra-uterine system. 
  Low dose long acting reversible contraceptive. Lasts for up to 3 years - not recommended as first line for nulliparous women.

• Levonorgestrel 19.5mg intra-uterine system. 
  Low dose long acting reversible contraceptive. Lasts for up to 5 years 

• Levonorgestrel 52mg in a T-shaped intra-uterine system. 
• For idiopathic menorrhagia. Especially in women requiring (reversible) contraception. Also used for protection from endometrial hyperplasia during oestrogen replacement therapy. Lasts for up to 6 years - for use in accordance with agreed guidelines.

First choice

• TT380 Slimline® Intrauterine device – replacement every 10 years.
• Mini TT380 Slimline® Intrauterine device – replacement every 5 years.
• T-Safe Cu380A® Intrauterine device – replacement every 10 years.

Alternatives

• Nova T 380® Intrauterine device – replacement every 5 years.

• Levonorgestrel is recommended for patients who present at up to 72 hours following unprotected intercourse, and the use of ulipristal should be second-line to the use of a copper containing IUCD.

• Recommended by NTAG as the preferred drug treatment option for post-coital contraception for patients who present between 72 and 120 hours following unprotected intercourse.

• 1mg, 2mg and 4mg tablets

• Doxazosin MR preparations are classified as BLACK - not approved

• 500microgram tablets

• Capsules: 500micrograms

• Tablets: 5mg

• MR Tablets - 7.5mg, 15mg

• Capsules: 20mg, 40mg
• Moderate to severe stress incontinence in combination with supervised pelvic floor excercises only

•  MR Tablets - 4mg, 8mg

• Tablets: 15mg

• Tablets: 20mg

• Approved for use when antimuscarinics don’t work, are not suitable or side effects are unacceptable, in line with NICE guidance. 

• Oxybutinin patch 36mg (releases approximately 3.6mg in 24 hours). 
• Approved for patients in whom two antimuscarinics have proved to be efficacious but the side effects are intolerable, or for patients who cannot swallow tablets.

• 75mg film-coated tablets
  • Approved for treating symptoms of overactive bladder syndrome in adults in line with NICE

• Methylphenidate is approved for use as a third line option (after e.g. antimuscarinics, imipramine, and pelvic floor exercises) in the treatment of giggle incontinence in children. Its use should be subject to a therapeutic trial to be reviewed after two months and considered for Shared Care if patients have been shown to respond after the trial period.

• The following methylphenidate formulations are approved for giggle incontinence:
  
  • 5mg & 10mg tablets.
  • 10mg, 20mg & 30mg m/r capsules (Equasym XL®).
  • 18mg, 27mg & 36mg m/r tablets (Xaggitin® XL)

• Existing patients who are prescribed Concerta® XL should be reviewed and switched to Xaggitin® XL as appropriate
• Xaggitin® XL is bioequivalent to Concerta® XL
• The effects of Equasym® XL last for about 8 hours compared with about 12 hours for Xaggitin® XL. 

• Vaginal Devices for female stress urinary incontinence (e.g. Diveen, Contiform, Efemia)
• Approved for use in line with NTAG / NICE
• Product should only be initiated by a specialist pelvic health physiotherapists and specialist nurses

• 10mg, 25mg and 50mg tablets
• 25mg in 5ml sugar-free oral solution is also approved for use.
•  Green plus for the treatment of nocturnal enuresis in children aged 6 years and above when organic pathology, including spina bifida and related disorders, have been excluded and no response has been achieved to all other non-drug and drug treatments, including antispasmodics and vasopressin-related products.Should only be prescribed by a healthcare professional with expertise in the management of persistent enuresis

• The following formulations are approved:
  
  • 100microgram and  200 microgram tablets;
  • 120 microgram sublingual tablets. 
  
  
• Note: nasal formulations no longer licensed for treating nocturnal
  enuresis (see section 6.5.2 for other formulations).

• Oral lyophilisates: 25microgram, 50 microgram

• 10mg and 25mg tablets
• 25mg in 5ml syrup is also approved. unlicensed.

• Prefilled syringe: 120mg/50ml

• potassium citrate 3g & citric acid 500mg in 10ml

Note: for the treatment of  mild cystitis potassium citrate mixture is suitable for self-care.

• 100mg capsules

• Approved for treating bladder pain in line with NICE

• For instillation into the bladder.

• Ialuril® is a 50ml solution for instillation into the bladder approved as second line treatment in patients who have failed Cystistat.

• Approved the treatment of:
  
  
  
  • Interstitial cystitis/painful bladder syndrome
  
  
  • Radiation cystitis
  
  
  • Recurring bacterial cystitis
  
  
  • Overactive bladder
  
  
  
  

• 1.5% large volume solutions (up to 3 litres).

• Large volume solutions (up to 3 litres).

• Large volumes  - up tp 3 litres.

• Whitmore cocktail is a 60ml bladder installation containing hydrocortisone 100mg, heparin Sodium 10,000units, and bupivacaine 50mg in Sodium Chloride 0.9%.

• Chlorhexidine 0.02% (1 in 5,000) solution in 100ml sachets.

• Sodium chloride 0.9% solution in 100ml sachets.

• Solution R 2 x 30ml sachets (citric acid 6%, gluconolactone 0.6%, magnesium carbonate 2.8%, disodium edetate 0.01%)

• Solution G 2 x 30ml sachets (citric acid 3.23%, magnesium oxide 0.38%,
  sodium bicarbonate 0.7%, disodium edetate 0.01%)

• 10mg and 20mg tablets
  • Approved for the treatment of erectile dysfunction
  • Also approved for specialist use in treating secondary Raynaud's disease. 
• 5mg tablets (once daily) 
  • Approved for the treatment of erectile dysfunction (in accordance with SLS criteria)

• 5mg, 10mg and 20mg tablets
  • Approved for the treatment of erectile dysfunction (in accordance with SLS criteria)

• Vitaros® 3mg/g cream
• Muse® 500microgram, and 1mg.

Treatment with alprostadil cream (Vitaros®) is NOT approved for use in County Durham and Tees Valley

• 25microgram/phentolamine 2mg solution for injection. 
• Approved as first choice intracavernosal injection option.
  • Approved for the treatment of erectile dysfunction (in accordance with SLS criteria)

• Approved as the second choice intracavernosal injection option.
• Caverject® 10 & 20 microgram injections (Caverject® dual chamber injections are easier to use and less expensive than the vials).
• Viridal Duo® 10, 20 and 40 microg starter pack and dual chamber injection (approved for use whilst supply issues surrounding Caverject® are ongoing).
  • Approved for the treatment of erectile dysfunction (in accordance with SLS criteria)

• Tablets: 50mg

• Tablets: 20mg

• 500mg tablets
• For fertility indications
• Also approved for polycystic ovarian syndrome (PCOS)